Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...
2024-03-22 10:00:33 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
2024-02-01 12:02:00 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma Read the full article on Seeking Alpha For further details see: GT Bio...
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® pla...
The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisor...
2023-12-04 10:55:06 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma For further details see: GT Biopharma submits IND to FDA for CD33+ leukemia th...
BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced the sub...
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced positiv...
2023-11-01 09:35:34 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma For further details see: GT Biopharma GAAP EPS of -$0.06
IND submission for GTB-3650, 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia, expected in Q4 2023 Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia anticipated in 2024 Cash of approximately $16 million a...
News, Short Squeeze, Breakout and More Instantly...
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025 GTB-5550 TriKE ® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025 GTB-5550 Phase 1 dose escalation basket trial initiation expected in 20...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 16.4% to $0.199 on volume of 720,586,242 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 74.8% to $1.8 on volume of 682,362,254 shares Pineapple Energy Inc. (PEGY) rose 80.3% to $0.1...